Hemab Therapeutics Inc. Common Stock
COAG | NASDAQ
$41.38
+$0.96 (+2.38%)
At close: Oct 30, 2026, 3:59 PM ET
$41.66
+$0.28 (+0.68%)
After-hours:
Oct 30, 2026, 7:48 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 |
|---|---|
Net Income | -63.91M |
Depreciation & Amortization | 304K |
Stock-Based Compensation | 2.01M |
Other Working Capital | -1.22M |
Other Non-Cash Items | -1.23M |
Deferred Income Tax | n/a |
Change in Working Capital | 1.36M |
Operating Cash Flow | -61.48M |
Capital Expenditures | -16K |
Cash Acquisitions | n/a |
Purchase of Investments | -252.5M |
Sales Maturities Of Investments | 171.03M |
Other Investing Acitivies | n/a |
Investing Cash Flow | -81.48M |
Debt Repayment | -120K |
Common Stock Repurchased | n/a |
Dividend Paid | n/a |
Other Financial Acitivies | n/a |
Financial Cash Flow | 156.3M |
Net Cash Flow | 13.57M |
Free Cash Flow | -61.49M |
Adj. Free Cash Flow | -63.5M |
Maintenance CapEx | -16K |
Growth CapEx | n/a |
Owner Earnings | -61.49M |
Add to Watchlist
Select watchlists to add or remove COAG